Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

BACKGROUND: This study aimed to explore the molecular mechanism and clinical relevance of iguratimod in the regulation of human B cell terminal differentiation. METHODS: An in vitro human antibody-secreting cell (ASC) differentiation system was established to test the effect of iguratimod. B cell ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Yan, Liu, Mei, Tang, Longhai, Du, Fang, Liu, Yuanhua, Hao, Pei, Fu, Qiong, Guo, Qiang, Yan, Qingran, Zhang, Xiaoming, Bao, Chunde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458835/
https://www.ncbi.nlm.nih.gov/pubmed/30971291
http://dx.doi.org/10.1186/s13075-019-1874-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458835/
https://www.ncbi.nlm.nih.gov/pubmed/30971291
http://dx.doi.org/10.1186/s13075-019-1874-2

Ejemplares similares